Browsing category:

Synthetic Peptide


Polycystic Ovarian Syndrome

Cetrorelix CAS No: 120287-85-6 Cetrorelix is traditionally used as fertility API that binds to a hormone receptor to stop gonadotropin secretion. While it may be associated with women undergoing ovarian stimulation, it appears as though there’s more to this API that meets the eye. This synthetic decapeptide is being studied to help with a variety of conditions, including the[…]

Read More

Known as the brand name Byetta in the United States, which is marketed by AstraZeneca, Exenatide is a GLP-1 analog that is currently offered as an injectable treatment for type 2 diabetes. In mid-January 2015 Oramed Pharmaceuticals was granted a patent in Israel for the oral administration of Exenatide. As an effectual therapy for patients[…]

Read More

Used to regulate hormone responses in female patients undergoing infertility treatment, Cetrorelix, is also known as the brand name Cetrotide. On April 17, 2013 Aeterna Zentaris announced the transfer of the manufacturing rights of this powerhouse product to Merck Serono. With the patent for Cetrotide set to expire on April 23, 2019, this transfer of[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service